Langerhans Cell Histiocytosis Clinical Trials

42 clinical trials for Langerhans Cell Histiocytosis across international registries, including 11 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Histiocytic Disorder Follow-up Study — RECRUITING
• Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib — RECRUITING · PHASE2
• Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis — RECRUITING · NA
• Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions — RECRUITING · NA
• Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH — RECRUITING · PHASE2
• Mirdametinib in Histiocytic Disorders — RECRUITING · PHASE2
• Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) — RECRUITING · PHASE3
• Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children — RECRUITING · PHASE2
• To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH — RECRUITING · PHASE2
• PHASE 2 STUDY OF TOVORAFENIB (DAY101) IN RELAPSED AND REFRACTORY LANGERHANS CELL HISTIOCYTOSIS — RECRUITING · PHASE2
• LCH-IV INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR CHILDREN AND ADOLESCENTS WITH LANGERHANS CELL HISTIOCYTOSIS — RECRUITING
• LCH-A1, first international study for Langerhans Cell Histiocytosis in adults — ACTIVE_NOT_RECRUITING · PHASE2
• Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease — SUSPENDED · NA
• Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis — NOT_YET_RECRUITING · PHASE2
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) — ACTIVE_NOT_RECRUITING · PHASE2
• Lenalidomide for Adult Histiocyte Disorders — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders — ACTIVE_NOT_RECRUITING · PHASE2
• LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis — TERMINATED · PHASE3
• LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis — ACTIVE_NOT_RECRUITING · PHASE2
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. — NOT_YET_RECRUITING · PHASE2
• Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH — ACTIVE_NOT_RECRUITING · PHASE2
• CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation — ACTIVE_NOT_RECRUITING · PHASE1
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) — COMPLETED · PHASE2
• Denosumab for the Treatment of Adult LCH — COMPLETED · PHASE2
• LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study — OTHER
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma — COMPLETED · PHASE2
• The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation — OTHER · PHASE2
• A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation — OTHER · PHASE2
• Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis — OTHER · PHASE1
• A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol — OTHER · PHASE3
• Central China Rosai-Dorfman Disease Registry — OTHER · PHASE4
• AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis — OTHER · PHASE2
• Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis — OTHER · PHASE2
• A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis — COMPLETED · PHASE2
• Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis — COMPLETED
• Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis — COMPLETED · PHASE2
• Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement — COMPLETED
• T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders — TERMINATED · PHASE2
• Stem Cell Transplant for Immunologic or Histiocytic Disorders — COMPLETED · PHASE2
• PHASE II STUDY OF CLOFARABINE IN PATIENTS WITH RECURRENT OR REFRACTORY LANGERHANS CELL HISTIOCYTOSIS — COMPLETED · PHASE2
• Clofarabine for Langerhans in Pedi — WITHDRAWN · PHASE2
• Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH — COMPLETED · PHASE2

Refine this search